Strong INTERPHEX 2013 an Indicator of Industry Regrowth - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Strong INTERPHEX 2013 an Indicator of Industry Regrowth


More than 12,000 industry professionals, including 8,100 show attendees, participated in INTERPHEX 2013, a 20% increase over the 2012 show, the show organizers report. The event, held April 23-25 at the Javits Center in New York, gave visitors the opportunity to connect with vendors and suppliers, while receiving the latest information on tools, methodologies and regulatory knowledge.

Congressman Bill Cassidy M.D.’s keynote presentation, “Policy Recommendations for Improving Patient Access to Drugs in Shortage”, offered potential improvements to the current reimbursement system to avoid future drug shortages. Another keynote session entitled “Reorganizing for the Future: Succeeding in the New Pharmaceutical Industry” featured Rajesh Nair, M.D., President of Indegene. Jim Miller, President, PharmSource Information Services, Inc., presented Recalibrating The Pharmaceutical Services Opportunity, in a third keynote, sponsored by Pharmaceutical Technology magazine.


PharmTech Publisher Mike Tracey (l) and Bob Stewart, Industry Vice President, INTERPHEX Events, meet on the floor of INTERPHEX 2013.
Buyers had the opportunity to connect and network with new suppliers displaying the latest technologies. Exhibit Hall Technology Floor Tours  offered critical insights followed by a walking tour to select vendors to showcase the latest technology and equipment on the Show Floor.

Russ Somma, PhD, INTERPHEX Advisory Board Member and Conference Speaker, stated, “Our event formula entailed attendees first be given real-time knowledge within the conference sessions that they could take to the Exhibit Hall to source specific organizational needs. We were confident that once the event ended our attendees could return to their firms and implement quickly what was gleaned at INTERPHEX. Learning, networking and implementation: a simple formula that can yield unprecedented success.” “We’re thrilled with the signs of industry optimism that were evident at this year’s INTERPHEX. We saw an increased demand for product sourcing with a higher number of open industry projects fueling a surge in attendance, “ noted Bob Stewart, Industry Vice President, INTERPHEX Events. “We at INTERPHEX will continue to bring insightful and critical information to our future attendees, and we look forward to seeing all next year, March 18-20, 2014 at the Javits Center in New York City.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here